TSHAClinical Trials•globenewswire•
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sentiment:Negative (30)
Summary
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire